论文部分内容阅读
用细胞毒性试验检测了24例典型的系统性红斑狼疮(SLE)患者的血清,并以10例淋巴增殖性疾患(4例慢性淋巴细胞性白血病、6例淋巴网细胞瘤)病人和10例其他自身免疫性疾患病人的血清作对照。结果:22例SLE患者细胞毒性抗体阳性,2例阴性。20例对照中仅1例慢性淋巴细胞性白血病患者细胞毒性抗体阳性。这些淋巴细胞毒性抗体可出现在活动性SLE患者及经治疗而处于缓解的患者中(即使在抗核抗体变为阴性后仍然存在),重复检查证明这些抗体可持续阳性达38个月。故作者认为淋巴细胞毒性抗体阳性对SLE的诊断是一有价值的参数。用纯T或B淋巴细胞悬液作实验,以及分别用慢性淋巴细胞性白血病患者的周围血淋巴
Serum was detected in 24 patients with systemic lupus erythematosus (SLE) using a cytotoxicity assay and 10 patients with lymphoproliferative disorders (4 chronic lymphocytic leukemia and 6 lymphocytoma) and 10 other patients Serum of patients with autoimmune disorders as a control. Results: The cytotoxic antibodies were positive in 22 SLE patients and 2 negative. Only 1 of 20 controls was positive for cytotoxic antibodies in patients with chronic lymphocytic leukemia. These lymphocytotoxic antibodies can appear in patients with active SLE and in patients who are treated and in remission (even after antinuclear antibodies become negative), and repeat tests show that these antibodies are consistently positive for up to 38 months. Therefore, the authors believe that the positive antibody to lymphocytosis is a valuable parameter for the diagnosis of SLE. Experiments with neat T or B lymphocyte suspensions and peripheral blood lymph nodes in patients with chronic lymphocytic leukemia